Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy

Gigin Lin, Lan Yan Yang, Yu Chun Lin, Yu Ting Huang, Feng Yuan Liu, Chun Chieh Wang, Hsin Ying Lu, Hsin Ju Chiang, Yu Ruei Chen, Ren Chin Wu, Koon Kwan Ng, Ji Hong Hong, Tzu Chen Yen, Chyong Huey Lai*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

16 Scopus citations

Abstract

Objectives: To develop and validate a prognostic model of integrating whole-tumour apparent diffusion coefficient (ADC) from pretreatment diffusion-weighted (DW) magnetic resonance (MR) imaging with human papillomavirus (HPV) genotyping in predicting the overall survival (OS) and disease-free survival (DFS) for women with stage IB–IV cervical cancer following concurrent chemoradiotherapy (CCRT). Methods: We retrospectively analysed three prospectively collected cohorts comprising 300 patients with stage IB–IV cervical cancer treated with CCRT in 2007–2014 and filtered 134 female patients who underwent MR imaging at 3.0 T for final analysis (age, 24–92 years; median, 54 years). Univariate and multivariate Cox regression analyses were used to evaluate the whole-tumour ADC histogram parameters, HPV genotyping and relevant clinical variables in predicting OS and DFS. The dataset was randomly split into training (n = 88) and testing (n = 46) datasets for construction and independent bootstrap validation of the models. Results: The median follow-up time for surviving patients was 69 months (range, 9–126 months). Non-squamous cell type, ADC10 <0.77 × 10-3 mm2/s, T3-4, M1 stage and high-risk HPV status were selected to generate a model, in which the OS and DFS for the low, intermediate and high-risk groups were significantly stratified (p < 0.0001). The prognostic model improved the prediction significantly compared with the International Federation of Gynaecology and Obstetrics (FIGO) stage for both the training and independent testing datasets (p < 0.0001). Conclusions: The prognostic model based on integrated clinical and imaging data could be a useful clinical biomarker to predict OS and DFS in patients with stage IB–IV cervical cancer treated with CCRT. Key points: • ADC10is the best prognostic factor among ADC parameters in cervical cancer treated with CCRT • A novel prognostic model was built based on histology, ADC10, T and M stage and HPV status • The prognostic model outperforms FIGO stage in the survival prediction.

Original languageEnglish
Pages (from-to)556-565
Number of pages10
JournalEuropean Radiology
Volume29
Issue number2
DOIs
StatePublished - 01 02 2019

Bibliographical note

Publisher Copyright:
© 2018, European Society of Radiology.

Keywords

  • Cervical cancer
  • Chemoradiotherapy
  • Diffusion magnetic resonance imaging
  • Human papillomavirus
  • Prognosis

Fingerprint

Dive into the research topics of 'Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy'. Together they form a unique fingerprint.

Cite this